A phase two clinical trial of the personalized peptide vaccine for the recurrence prevention in pediatric cancer patients
- Conditions
- Pediatric cancer patients
- Registration Number
- JPRN-UMIN000030249
- Lead Sponsor
- Kurume University Cancer Vaccine Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
The following patients must be excluded: 1) Patients with severe symptoms (active and severe infections, circulatory diseases, respiratory diseases, kidney diseases, immunodeficiency, disturbance of coagulation). 2) Active double cancer (synchronous double cancer and meta-chronous double cancer within three disease-free years), excluding carcinoma in situ (lesions equal to intra-epithelial or intra-mucosal cancer), judging to have been cured with local treatment. 3) Patients with the past history of severe allergic reactions. 4) Patients who hope for pregnancy 5) Patients who do not accept contraception from the 1st vaccination until 70 days after the last vaccination. 6) Patients who are judged inappropriate for entry to this trial by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method